Everolimus

Cat. No. 6188 1 次引用提交评论说明书 / 分析证书（CoA） / 化学品安全技术说明书（SDS）

Pricing	Availability		Qty

说明： mTOR inhibitor; Immunosuppressant

别名： RAD001

化学名： 42-O-(2-Hydroxyethyl)rapamycin

纯度： ≥98% (HPLC)

引用文献 (1)

文献 (2)

通路 (1)

生物活性技术数据溶解性计算器说明书参考文献

生物活性 for Everolimus

Everolimus is a mTOR inhibitor. Inhibits tumor proliferation in vitro and in vivo. Inhibits VEGF-induced HUVEC proliferation in vitro, but does not affect tumor vascular permeability in mouse models. Immunosuppressant. Activates autophagy.

技术数据 for Everolimus

分子量	958.22
公式	C₅₃H₈₃NO₁₄
储存	Store at -20°C
纯度	≥98% (HPLC)
CAS Number	159351-69-6
PubChem ID	100926147
InChI Key	HKVAMNSJSFKALM-GKUWKFKPSA-N
Smiles	[H][C@@]12CC[C@H]([C@@](O1)(C(C(N3CCCC[C@]3(C(O[C@@](CC([C@@H](/C=C([C@H]([C@H](C([C@@H](C[C@@H](/C=C/C=C/C=C([C@@H](OC)C2)\C)C)C)=O)OC)O)\C)C)=O)([C@@H](C[C@@H]4CC[C@H]([C@H](OC)C4)OCCO)C)[H])=O)[H])=O)=O)O)C

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

溶解性数据 for Everolimus

	溶剂	最高浓度 mg/mL	最高浓度 mM
溶解性
	DMSO	95.82	100
	ethanol	95.82	100

制备储备液 for Everolimus

以下数据基于产品分子量 958.22。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

浓度/溶剂体积/质量	1 mg	5 mg	10 mg
1 mM	1.04 mL	5.22 mL	10.44 mL
5 mM	0.21 mL	1.04 mL	2.09 mL
10 mM	0.1 mL	0.52 mL	1.04 mL
50 mM	0.02 mL	0.1 mL	0.21 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

产品说明书 for Everolimus

分析证书/产品说明书

化学品安全技术说明书

参考文献 for Everolimus

参考文献是支持产品生物活性的出版物。

Lane et al (2009) mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin.Cancer Res. 15 1612 PMID: 19223496

Sedrani et al (1998) Chemical modification of rapamycin: the discovery of SDZ RAD. Transplant Proc. 30 2192 PMID: 9723437

Galluzzi et al (2017) Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles. Nat.Rev.Drug.Discov. PMID: 28529316

If you know of a relevant reference for Everolimus, please let us know.

按标靶查看相关产品

按产品操作查看相关产品

查看全部 mTOR Inhibitors

关键词: Everolimus, Everolimus supplier, mTOR, inhibitors, inhibits, immunosuppressants, RAD001, Autophagy, 6188, Tocris Bioscience

1 篇 Everolimus 的引用文献

引用文献是使用了 Tocris 产品的出版物。 Everolimus 的部分引用包括：

Lisa D et al (2023) A Ubiquitination Cascade Regulating the Integrated Stress Response and Survival in Carcinomas. Cancer Discov 13 766-795 PMID: 36576405

您是否知道使用了 Tocris Everolimus 的优秀论文？请告知我们.

Everolimus 的评论

目前没有该产品的评论。 Be the first to review Everolimus and earn rewards!

Have you used Everolimus?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。

Cancer Metabolism Research Product Guide

This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including:

Glycolysis
Tricarboxylic Acid Cycle
Lipidogenesis
1C Metabolism and Nucleic Acid Synthesis
Drivers of Metabolic Reprogramming
pH and Redox Balance

Cancer Metabolism Poster

This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.

Pathways for Everolimus

mTOR Signaling Pathway

mTOR is a serine/threonine kinase that nucleates at multiprotein complexes mTORC1 and mTORC2. Signaling by these complexes regulates cell growth, proliferation and survival.